Wang Y. et al. (2020) noted increased levels of both DR5 and TRAIL in MI contexts, with a corresponding reduction in cardiomyocyte death and inflammation upon blocking TRAIL. Similarly, Cui et al. (2010) observed that blocking the TRAIL-DR5 interaction with a soluble DR5 antagonist decreased ischemic cell death following global cerebral ischemia, suggesting a potential neuroprotective strategy for ischemic stroke through inhibition of the TRAIL-DR5 system. The gene discussed is TNFRSF10B; the disease is ischemic stroke.